

## Enzastaurin

## Chemical Properties

CAS No. : 170364-57-5


Formula: C32H29N5O2

Molecular Weight: 515.6

Appearance: no data available

Storage: store at low temperature

Powder: -20°C for 3 years | In solvent: -80°C for 1 year



## Biological Description

Description	Enzastaurin (LY317615) (LY317615) is an effective PKC $\beta$ selective inhibitor (IC <sub>50</sub> : 6 nM), 6- to 20-fold selectivity against PKC $\alpha$ / $\gamma$ / $\epsilon$ .
Targets(IC <sub>50</sub> )	Apoptosis, Autophagy, PKC
In vitro	Application of Enzastaurin consistently leads to significant dose-dependent growth inhibition in a variety of MM cell lines, including MM.1S, MM.1R, RPMI 8226 (RPMI), RPMI-Dox40 (Dox40), NCI-H929, KMS-11, OPM-2, and U266, achieving half-maximal inhibitory concentrations (IC <sub>50</sub> ) ranging from 0.6 to 1.6 $\mu$ M. This compound directly targets human tumor cells by promoting apoptosis and hindering cell proliferation. It specifically reduces the phosphorylation of GSK3 $\beta$ ser9, ribosomal protein S6S240/244, and AKTThr308, while not affecting VEGFR phosphorylation. [1] Furthermore, Enzastaurin elevates apoptosis rates in CTCL's malignant lymphocytes and shows increased cytotoxicity when used alongside GSK3 inhibitors. A notable synergy is observed when Enzastaurin is combined with the GSK3 inhibitor AR-A014418, leading to raised levels of $\beta$ -catenin total protein and its mediated transcription. Blocking this transcription or reducing $\beta$ -catenin expression through shRNA achieves similar cytotoxic effects to the Enzastaurin and AR-A014418 combination. This treatment pair also notably diminishes mRNA levels and surface expression of CD44. [2]
In vivo	The combined treatment of xenografts with Enzastaurin and radiation resulted in a greater reduction in microvessel density compared to either treatment alone, correlating with delayed tumor growth. [3]
Kinase Assay	Kinase inhibition assays: The inhibition of PKC $\beta$ II, PKC $\alpha$ , PKC $\epsilon$ , or PKC $\gamma$ activity by enzastaurin is determined using a filter plate assay format measuring 33P incorporation into myelin basic protein substrate. Reactions are done in 100 $\mu$ L reaction volumes in 96-well polystyrene plates with final conditions as follows: 90 mM HEPES (pH 7.5), 0.001% Triton X-100, 4% DMSO, 5 mM MgCl <sub>2</sub> , 100 $\mu$ M CaCl <sub>2</sub> , 0.1 mg/mL phosphatidylserine, 5 $\mu$ g/mL diacetyl glycerol, 30 $\mu$ M ATP, 0.005 $\mu$ Ci/ $\mu$ L 33ATP, 0.25 mg/mL myelin basic protein, serial dilutions of enzastaurin (1-2,000 nM), and recombinant human PKC $\beta$ II, PKC $\alpha$ , PKC $\epsilon$ , or PKC $\gamma$ enzymes (390, 169, 719, or 128 pM, respectively). Reactions are started by addition of the enzyme and incubated at room temperature for 60 minutes. They are then quenched with 10% H <sub>3</sub> PO <sub>4</sub> , transferred to multiscreen anionic phosphocellulose 96-well filter plates, incubated for 30 to 90 minutes, filtered and washed with 4 volumes of 0.5% H <sub>3</sub> PO <sub>4</sub> on a vacuum manifold. Scintillation cocktail is

added and plates are read on a Microbeta scintillation counter. IC50 values are determined by fitting a three-variable logistic equation to the 10-point dose-response data using ActivityBase 4.0.

## Cell Research

Induction of apoptosis by enzastaurin is measured by nucleosomal fragmentation and terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) and staining in HCT116 and U87 mg cell lines. Briefly,  $5 \times 10^3$  cells are plated per well in 96-well plates (1% FBS-supplemented media conditions), incubated with or without Enzastaurin for 48 to 72 hours. The absorbance values are normalized to those from control-treated cells to derive a nucleosomal enrichment factor at all concentrations as per the manufacturer's protocol. The concentrations studied ranges from 0.1 to 10  $\mu$ M. In situ TUNEL staining is assayed with the In situ Cell Death Detection, Fluorescein kit. Cells ( $7.5 \times 10^4$ ) are plated per well in 6-well plates and incubated 72 hours in 1% FBS-supplemented media Enzastaurin. Fluorescein-labeled DNA strand breaks are detected with the BD epics flow cytometer. Ten thousand, single-cell, FITC-staining events are collected for each test. (Only for Reference)

## Solubility Information

## Solubility

DMSO: 10.3 mg/mL (19.98 mM), Sonication is recommended.  
( $< 1$  mg/ml refers to the product slightly soluble or insoluble)

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9395 mL	9.6974 mL	19.3949 mL
5 mM	0.3879 mL	1.9395 mL	3.879 mL
10 mM	0.1939 mL	0.9697 mL	1.9395 mL
50 mM	0.0388 mL	0.1939 mL	0.3879 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

## Reference

Graff JR, et al. Cancer Res, 2005, 65(16), 7462-7469.

Feng J, Chen Z, Ma Y, et al. AKAP1 contributes to impaired mtDNA replication and mitochondrial dysfunction in podocytes of diabetic kidney disease. Int J Biol Sci. 2022, 18(10): 4026-4042

Rovedo MA, et al. J Invest Dermatol, 2011, 131(7), 1442-1449.

Podar K, et al. Blood, 2007, 109(4), 1669-1677.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

**This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use**

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 36 Washington Street, Wellesley Hills, MA 02481